Abvc BiopharmaABVC
13F holders, Q4 2024 (December 31)13holders +4
3new positions
0sold out
1famous investor
$0.59avg. 13F price*
At the end of Q4 2024, 13 institutions reported holding Abvc Biopharma Inc. (ABVC) in their 13F filings, up 4 from Q3 2024. 3 opened new positions and 0 sold out. The largest holders were Avantax Planning Partners, Inc. ($85K), Geode Capital Management, LLC ($47K) and Vanguard Group Inc. ($28K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Abvc Biopharma Inc.
- CUSIP
- 00091F304
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $33K |
| Exits | 0 | $0 |
All 13F filers, Q3 2024 → Q4 2024: 180,533 shares bought and 60 shares sold, net +180,473 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 13 holders
| Avantax Planning Partners, Inc. | 0.00% | Add +269.1% | 143,968 | $85K |
| Geode Capital Management, LLC | 0.00% | Add +10.7% | 79,285 | $47K |
| Vanguard Group Inc. | 0.00% | No change | 46,947 | $28K |
| Citadel Advisors | 0.00% | New | 40,743 | $24K |
| XTX Topco Ltd | 0.00% | Add +47.0% | 34,405 | $20K |
| Northern Trust Corp. | 0.00% | No change | 19,135 | $11K |
| Virtu Financial LLC | 0.00% | New | 15,935 | $9K |
| State Street Corp. | 0.00% | No change | 12,900 | $8K |
| Two Sigma Securities, LLC | 0.00% | Add +1.6% | 12,593 | $7K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -2.3% | 2,563 | $2K |
| SBI Securities Co., Ltd. | 0.00% | — | 662 | $391 |
| Bank of America Corp. | 0.00% | Add +3.9% | 81 | $48 |
| UBS Group AG | 0.00% | New | 10 | $6 |
"% of holder's portfolio" is ABVC's weight in each manager's 13F, not the share of Abvc Biopharma Inc. the manager owns.